Voya Investment Management LLC Has $7.74 Million Stock Position in Hologic, Inc. $HOLX

Key Points

• Voya Investment Management LLC decreased its stake in Hologic, Inc. by 9.7%, selling 13,515 shares, and now holds approximately 125,376 shares valued at $7.74 million.
• Several hedge funds increased their positions in Hologic during the first quarter, with institutional investors owning 94.73% of the company's stock.
• Hologic has seen recent upgrades from analysts, including Citigroup raising their rating from "neutral" to "buy" with a target price increase from $60 to $80.

Voya Investment Management LLC decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 125,376 shares of the medical equipment provider's stock after selling 13,515 shares during the period. Voya Investment Management LLC owned 0.06% of Hologic worth $7,744,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC increased its position in Hologic by 22.3% during the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after purchasing an additional 335 shares during the last quarter. United Services Automobile Association purchased a new stake in Hologic during the first quarter worth approximately $347,000. SG Americas Securities LLC grew its stake in Hologic by 116.6% during the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after buying an additional 5,172 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Hologic during the first quarter worth approximately $641,000. Finally, Cambridge Investment Research Advisors Inc. grew its stake in Hologic by 1.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after buying an additional 528 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Performance

Shares of HOLX stock traded down $1.94 during trading hours on Friday, reaching $66.33. The stock had a trading volume of 8,515,121 shares, compared to its average volume of 1,762,988. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The firm has a 50-day simple moving average of $66.47 and a 200-day simple moving average of $62.75. The firm has a market capitalization of $14.75 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 2.47 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the company earned $1.06 EPS. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several research reports. Stephens reiterated an "overweight" rating and set a $78.00 price objective on shares of Hologic in a research note on Thursday. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Evercore ISI upped their target price on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Finally, Mizuho set a $75.00 target price on shares of Hologic in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $79.38.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.